Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsThe body's inability to distinguish between self- and non-self substances is what causes autoimmune disorders that are not well understood, but some pathogens or drugs were testified to cause changes in normal immune function. Currently, the main drugs used to treat autoimmune diseases are hormones, vitamins, small-molecule immunosuppressants, and some antibody drugs. In contrast, anti-autoimmune disease-specific antibodies are highly specific and highly targeted. In contrast, anti-autoimmune disease-specific antibodies are highly specific and targeted, offering more significant therapeutic effects. Creative Biolabs offers a comprehensive service to target anti-autoimmune-disorder-specific antibodies. Based on our hybridoma platform and phage display platform, we will provide you with high-quality custom antibody production services.
Compared to hormones and small molecule immunosuppressive drugs, antibody-based drugs have higher specificity, targetability, and reduced toxic side effects. With the development of antibody technology and in-depth research on autoimmune diseases, more highly specific autoimmune disease targets have been identified and thus anti-autoimmune-disorder-specific antibodies developed.
TNF-α is the most important target for the development of anti-autoimmune-disorder-specific antibodies mainly produced by activated macrophages, T lymphocytes, and NK cells. The main function of TNF-α is to regulate immune cells. As an endogenous pyrogen, it is capable of causing fever, apoptosis, tissue tumorigenesis, and viral replication. Most importantly, it can regulate the early response phase of the inflammatory immune process by modulating the downstream TNFR1 and TNFR2 signaling pathways. A number of anti-TNF-α antibodies have been used for the treatment of rheumatoid arthritis, inflammatory bowel disease, and other autoimmune diseases.
Integrins are also important targets, which are transmembrane cell adhesion proteins that aid in adhesion between cells and between cells and the extracellular matrix. Its receptors can influence a large number of downstream proteins that control cell motility, survival, proliferation, and differentiation. In inflammatory and immune responses, integrins can have an important role in leukocyte recruitment. In addition, it regulates leukocyte activation and survival. Anti-integrin antibodies are important for the management of multiple sclerosis and refractory Crohn's disease.
The role of B cells in autoimmune diseases cannot be overstated. Not only do they produce autoantibodies, they are also antigen-presenting cells. They activate T cells and produce cytokines including IL-1, IL-4, IL-6, IL-8, IL-10, IL-12, and TNF-α. Therefore, B-cell depletion can effectively improve the clinical manifestations of many autoimmune diseases. Current targets with B-cell depletion as the main mechanism include CD20 and the BlyS/APRIL system, of which CD20 is a transmembrane protein expressed on the surface of B cells, and targeting CD20 can distinguish precursor B cells, progenitor B cells, and plasma cells, remove autoimmune memory B cells, and reconstitute the transitional B cell population. The BlyS/APRIL system is an important target in systemic lupus erythematosus (SLE). BlyS is essential in the maturation of B cells. Also, BlyS is able to promote the activation, proliferation, and differentiation of T cells. In contrast, APRIL binds mainly to antigen-presenting B cells, binds to BCMA, and promotes long-term plasma cell survival. Related studies have shown that anti-BlyS/APRIL antibodies are potent agents to treat SLE.
Anti-autoimmune-disorder-specific antibodies have been shown to play an important role in the treatment of many autoimmune disorders. Based on our extensive hands-on experience, Creative Biolabs is pleased to share our knowledge and experience in anti-autoimmune disorders-specific antibodies to help your research run smoothly.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
